In the pharmaceutical context, the intranasal route, in addition to predominantly local drug application, is also of great interest for systemic application. The COVID-19 pandemic revealed once again the role of the nose as a portal of entry for pathogens. The nasal mucosa has shown to be not only the main portal of entry of the SARS-CoV-2 virus into the human body, but also an important site for replication of the virus. Within this context, the topic of the nasal mucosa as a site of entry for viruses, but also as a route of administration of systemic therapies and vaccines, is intensively discussed.
Read more about chances and challenges of intranasal applications for systemic drug delivery in our blog.
Contact us
Newsletter
Hotline
